IMNM•benzinga•
Imunon Announces Phase 1 Trial Results For IMNN-101 DNA Vaccine Showing 2-4x Antibody Increase Vs. Omicron Variant With No Serious Adverse Effects In 24 Participants; Vaccine Demonstrated Cross-Reactivity With New Variants
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 26, 2025 by benzinga